United States v. Lebeau, 654 F. App'x 826

Background

Conrad LeBeau and his company sold natural-product formulations and advertised disease‑related benefits (e.g., “reduces food allergies,” Lyme disease mitigation). The government charged four misdemeanors for introducing unapproved new drugs into interstate commerce under the FDCA.
LeBeau moved to dismiss, arguing (1) his products were foods/dietary supplements not “drugs,” (2) FDA approval was impossible because natural substances are unpatentable and § 355 requires a patent, and (3) prosecution violated his First Amendment commercial‑speech rights. The magistrate denied the motions.
LeBeau pleaded guilty to one count but reserved the right to appeal pretrial rulings. He later sought to withdraw his plea, claiming coercion and disputing the factual basis (saying he meant to advertise reduced “intolerances,” not “diseases”). The magistrate denied withdrawal and sentenced him to probation and a fine.
The district court affirmed: § 321(g)(1)(B) covers naturally occurring substances when intended for disease diagnosis, cure, mitigation, treatment, or prevention; § 355(b) does not require a patent; and using LeBeau’s statements as evidence of intent does not violate the First Amendment.
On appeal, the court reviewed denial of plea withdrawal for abuse of discretion and rejected LeBeau’s involuntariness and factual‑basis arguments, concluding his plea was knowing and his subjective intent contradicted objective promotional materials.

Issues

Issue	LeBeau's Argument	Government's Argument	Held
Whether naturally occurring products qualify as "drugs" under 21 U.S.C. § 321(g)(1)	§ 321(g) should not cover natural foods/herbs; Congress intended a narrower scope	§ 321(g)(1)(B) covers any material intended for disease‑related use, including natural substances	Court: § 321(g)(1)(B) includes natural substances when intended for disease diagnosis/treatment; product was a drug
Whether FDA approval is impossible absent a patent under 21 U.S.C. § 355	§ 355(b) requires a patent, and natural substances are unpatentable, so approval is impossible	§ 355(b) merely requires disclosure of any relevant patent numbers; it does not mandate obtaining a patent	Court: § 355 does not require a patent; LeBeau’s impossibility claim fails
Whether prosecution/penalizing claims about product benefits violates the First Amendment	Prohibiting truthful claims about health benefits infringes commercial speech	Government used LeBeau’s statements as evidence of intent (objective proof the product was a drug); evidentiary use of speech is permissible	Court: Use of statements to prove intent is lawful; speech evidentiary use does not violate First Amendment; conviction permissible
Whether district court abused discretion by denying motion to withdraw guilty plea	Plea was involuntary due to pressure and stress; factual basis lacking because intent was to treat "intolerances," not "diseases"	Plea colloquy shows plea was knowing; LeBeau conceded proffer and objective promotional materials show intent; subjective intent irrelevant	Court: No abuse of discretion; plea denial affirmed

Key Cases Cited

Wisconsin v. Mitchell, 508 U.S. 476 (1993) (evidentiary use of speech does not violate First Amendment)
Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n of N.Y., 447 U.S. 557 (1980) (framework for commercial‑speech regulation)
Nat’l Nutritional Foods Ass’n v. Mathews, 557 F.2d 325 (2d Cir. 1977) (promotional materials can show intended use under FDCA)
Nutrilab, Inc. v. Schweiker, 713 F.2d 335 (7th Cir. 1983) (FDCA treats naturally occurring substances as drugs when intended for disease‑related uses)
United States v. Articles of Drug for Veterinary Use, 50 F.3d 497 (8th Cir. 1995) (court may infer intent from objective promotional materials)
Whitaker v. Thompson, 353 F.3d 947 (D.C. Cir. 2004) (FDA may use labeling/speech to infer intent for unapproved‑drug determinations)
United States v. Caputo, 517 F.3d 935 (7th Cir. 2008) (unlawful promotion of unapproved drugs not protected commercial speech)
United States v. Redmond, 667 F.3d 863 (7th Cir. 2012) (standard of review for denial of plea withdrawal)
United States v. Collins, 796 F.3d 829 (7th Cir. 2015) (plea voluntariness and court may disbelieve claims of coercion)
United States v. Weathington, 507 F.3d 1068 (7th Cir. 2007) (same)